These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 1463272)

  • 1. The manifold actions of neurotensin, a trophotropic agent.
    Prange AJ
    Ann N Y Acad Sci; 1992; 668():298-306. PubMed ID: 1463272
    [No Abstract]   [Full Text] [Related]  

  • 2. [Neurotensin-like oligopeptides as potential antipsychotics: effect on dopamine system].
    Kost NV; Meshavkin VK; Batishcheva EIu; Sokolov OIu; Andreeva LA; Miasoedov NF
    Eksp Klin Farmakol; 2011; 74(10):3-6. PubMed ID: 22238978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The neurotensin receptor agonist NT69L suppresses sucrose-reinforced operant behavior in the rat.
    Boules M; Iversen I; Oliveros A; Shaw A; Williams K; Robinson J; Fredrickson P; Richelson E
    Brain Res; 2007 Jan; 1127(1):90-8. PubMed ID: 17113052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intramembrane interactions between neurotensin receptors and dopamine D2 receptors as a major mechanism for the neuroleptic-like action of neurotensin.
    Fuxe K; Von Euler G; Agnati LF; Merlo Pich E; O'Connor WT; Tanganelli S; Li XM; Tinner B; Cintra A; Carani C
    Ann N Y Acad Sci; 1992; 668():186-204. PubMed ID: 1361113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesocortical dopamine-neurotensin neurons. Possible opposite role of noradrenergic pathways on heteroregulations of dopamine (D1) and neurotensin postsynaptic receptors in the rat prefrontal cortex.
    Tassin JP; Trovero F; Hervé D; Blanc G; Glowinski J
    Ann N Y Acad Sci; 1992; 668():205-16. PubMed ID: 1334386
    [No Abstract]   [Full Text] [Related]  

  • 6. The manifold actions of neurotensin: a first synthesis.
    Prange AJ; Nemeroff CB
    Ann N Y Acad Sci; 1982; 400():368-75. PubMed ID: 6132578
    [No Abstract]   [Full Text] [Related]  

  • 7. Dopamine inhibition of neurotensin-induced increase in Ca2+ influx into rat pituitary cells.
    Memo M; Carboni E; Trabucchi M; Carruba MO; Spano PF
    Brain Res; 1985 Nov; 347(2):253-7. PubMed ID: 2415214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraventricular injection of neurotensin reduces dopamine D2 agonist binding in rat forebrain and intermediate lobe of the pituitary gland. Relationship to serum hormone levels and nerve terminal coexistence.
    von Euler G; Meister B; Hökfelt T; Eneroth P; Fuxe K
    Brain Res; 1990 Oct; 531(1-2):253-62. PubMed ID: 1981163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurotensin effects on brain dopaminergic systems.
    Haubrich DR; Martin GE; Pflueger AB; Williams M
    Brain Res; 1982 Jan; 231(1):216-21. PubMed ID: 7198926
    [No Abstract]   [Full Text] [Related]  

  • 10. Modulation of dopamine D3 receptor binding by N-ethylmaleimide and neurotensin.
    Liu Y; Hillefors-Berglund M; von Euler G
    Brain Res; 1994 Apr; 643(1-2):343-8. PubMed ID: 7913398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurotensin in vitro markedly reduces the affinity in subcortical limbic 3H-N-propylnorapomorphine binding sites.
    Agnati LF; Fuxe K; Benfenati F; Battistini N
    Acta Physiol Scand; 1983 Dec; 119(4):459-61. PubMed ID: 6320589
    [No Abstract]   [Full Text] [Related]  

  • 12. Antiparkinson-like effects of neurotensin in 6-hydroxydopamine lesioned rats.
    Jolicoeur FB; Rivest R; St-Pierre S; Drumheller A
    Brain Res; 1991 Jan; 538(2):187-92. PubMed ID: 1901504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioactive analogs of neurotensin: focus on CNS effects.
    Boules M; Fredrickson P; Richelson E
    Peptides; 2006 Oct; 27(10):2523-33. PubMed ID: 16882457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence that the stimulatory effect of neurotensin on dopamine release in rat nucleus accumbens slices is independent of dopamine D2-receptor activation.
    Reyneke L; Russell VA; Taljaard JJ
    Brain Res; 1990 Nov; 534(1-2):188-94. PubMed ID: 1981481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonization of the behavioral activation produced by direct stimulation of forebrain dopamine receptors caused by intraaccumbens injections of neurotensin.
    Ervin GN; Nemeroff CB
    Neuropsychopharmacology; 1988 Sep; 1(3):243-50. PubMed ID: 3150806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The discriminative stimulus effects of the neurotensin NTS1 receptor agonist PD149163 in rats: stimulus generalization testing with dopamine D1 and D2 receptor ligands.
    Prus AJ; Schuck CJ; Rusch KR; Carey LM
    Drug Dev Res; 2014 Mar; 75(2):47-58. PubMed ID: 24668440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioral evidence for differential neuropeptide modulation of the mesolimbic dopamine system.
    Kelley AE; Cador M
    Ann N Y Acad Sci; 1988; 537():415-34. PubMed ID: 2462397
    [No Abstract]   [Full Text] [Related]  

  • 18. Behavioral and neurochemical effect of daily injection with neurotensin into the ventral tegmental area.
    Kalivas PW; Taylor S
    Brain Res; 1985 Dec; 358(1-2):70-6. PubMed ID: 4075132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurotensin and cholecystokinin microinjected into the ventral tegmental area modulate microdialysate concentrations of dopamine and metabolites in the posterior nucleus accumbens.
    Laitinen K; Crawley JN; Mefford IN; De Witte P
    Brain Res; 1990 Jul; 523(2):342-6. PubMed ID: 1698106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions of neurotensin with brain dopamine systems.
    Nemeroff CB; Hernandez DE; Luttinger D; Kalivas PW; Prange AJ
    Ann N Y Acad Sci; 1982; 400():330-44. PubMed ID: 6132577
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.